Mastectomy Reconstruction Outcomes Consortium (MROC) Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The MROC Study seeks to evaluate and compare from the patient's point of view the leading options for breast reconstruction after mastectomy. This study will help patients, physicians, payers and policy makers better understand the various surgeries available for breast reconstruction. Although many women choose reconstruction, the number of options as well as their pros and cons can make decision making difficult and stressful. From this research, we hope to learn more about what works best for patients undergoing these operations.
| Condition |
|---|
|
Breast Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Mastectomy Reconstruction Outcomes Consortium (MROC) Study |
- Change from baseline in health-related quality of life. [ Time Frame: Change from baseline at 1 week, 3 months, 1 year and 2 years post-operatively. ] [ Designated as safety issue: No ]Patient reported outcome measures will include patient satisfaction, post-operative pain, body image, psycho-social functioning, physical functioning, and fatigue.
- The effects of race and ethnicity on reconstruction outcomes. [ Time Frame: Pre-operatively and at 1 week, 3 months, 1 year and 2 years postoperatively ] [ Designated as safety issue: No ]Although the study will not be adequately powered to analyze outcomes by procedure type within racial and ethnic categories, we will obtain descriptive statistics for the effects of race and ethnicity on breast reconstruction outcomes.
- Descriptive statistics on the relative costs of the eight procedure types. [ Time Frame: 2 years postoperatively ] [ Designated as safety issue: No ]Obtain descriptive statistics on the costs of each of the seven procedure types, to gain a better understanding of the cost differences between procedures.
| Estimated Enrollment: | 7170 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | July 2016 |
| Estimated Primary Completion Date: | July 2016 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Expander/Implant
Patients receiving expander/implant breast reconstruction procedures.
|
|
Lat Dorsi
Patients receiving latissimus dorsi breast reconstructions with or without implant.
|
|
PTRAM
Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
|
|
FTRAM
Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
|
|
DIEP
Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
|
|
SIEA
Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
|
|
S-GAP
Patients receiving superior gluteal artery perforator (S-GAP) breast reconstruction.
|
|
I-GAP
Patients inferior gluteal artery perforator (I-GAP) breast reconstruction.
|
Detailed Description:
Despite the growing use of breast conservation as primary therapy for breast cancer, mastectomy remains a common treatment option. Many patients choose to undergo breast reconstruction as an effective means of lessening the adverse impact of mastectomy on psychosocial functioning and quality of life. Despite these benefits, well-designed studies comparing the current choices from the patient's point of view are difficult (if not impossible) to come by. Previous research on breast reconstruction outcomes has also failed to include race and ethnicity as key variables. In order to actively participate in the reconstruction decision making process, breast cancer survivors need objective, up-to-date information on breast reconstruction outcomes from the patient's perspective.
The proposed Mastectomy Reconstruction Outcomes Consortium (MROC) Study will use a prospective cohort design to compare outcomes for the eight commonly used options for breast reconstruction: expander/implant, latissimus dorsi/implant (LD), pedicle transverse rectus abdominis musculocutaneous (PTRAM), free TRAM (FTRAM), deep inferior epigastric perforator (DIEP), superficial inferior epigastric artery (SIEA), superior gluteal artery perforator (SGAP) and inferior gluteal artery perforator (IGAP) techniques.
Outcomes assessed will include complications, postoperative pain, psychosocial well-being, physical functioning, fatigue, patient satisfaction and costs. The project will also evaluate the effects of race and ethnicity on reconstruction outcomes. Thirteen leading centers in the United States and Canada will participate. Together, these institutions perform over 3000 breast reconstructions annually. The five year study will evaluate patients preoperatively and at one week, three months, one year and two years following reconstruction. For data sources, the project will rely on medical and billing records, as well as a panel of generic and condition-specific patient-report outcome measures.
The MROC Study will benefit a variety of stakeholders in the healthcare marketplace: The project will provide consumers, providers, payers, and policy-makers with reliable, up-to-date information on the effectiveness and relative costs of surgical options for breast reconstruction, thereby promoting a more evidence-based approach to treatment and policy decision-making. Study findings will also assist health care organizations in designing systems of care tailored to the specific needs and preferences of diverse patient populations.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Women undergoing first-time breast reconstruction at one of 13 consortium sites.
Inclusion Criteria:
- Women who present themselves for reconstruction at one of 13 MROC centers
- Women undergoing one of the following types of breast reconstruction after mastectomy: tissue expander/implant, LD flap (with, or without implant), PTRAM flap, FTRAM flap, DIEP flap, S-GAP flap, I-GAP flap or SIEA flap.
- Immediate or delayed reconstruction
- Unilateral or bilateral reconstructions.
- Women receiving mastectomy for cancer prophylaxis, without history of breast cancer, will be eligible to participate.
Exclusion Criteria:
- Patients electing reconstruction following complications of breast augmentation, mastopexy (breast lift), or breast reduction will not be recruited for the study.
- Procedures performed following previously failed attempts at breast reconstruction will be excluded from the study, due to potential confounding by these previous surgeries.
Contacts and Locations| Contact: Edwin G. Wilkins, MD, MS | 734-936-6680 | ewilkins@umich.edu |
| Contact: Jennifer B. Hamill, MPH | 570-559-7912 | jenberry@umich.edu |
| United States, California | |
| University of California, Los Angeles | Recruiting |
| Los Angeles, California, United States, 90095-6960 | |
| Contact: Andrew Da Lio, M.D. 310-206-7521 adalio@mednet.ucla.edu | |
| Contact: Ivan Sanchez, B.S. 310-206-9401 isanchez@mednet.ucla.edu | |
| Principal Investigator: Andrew Da Lio, M.D. | |
| United States, District of Columbia | |
| Georgetown University Hospital | Recruiting |
| Washington, D.C., District of Columbia, United States, 20007 | |
| Contact: Scott Spear, M.D. 202-444-8612 spears@gunet.georgetown.edu | |
| Contact: Whitney Douglas 202-444-7060 Whitney.Douglas@gunet.georgetown.edu | |
| Principal Investigator: Scott Spear, M.D. | |
| United States, Georgia | |
| Georgia Institute for Plastic Surgery | Recruiting |
| Savannah, Georgia, United States, 31405 | |
| Contact: Richard Greco, M.D. 912-355-8000 plastxdoc@aol.com | |
| Contact: Teri Goolsby, RN (912) 355-8000 Terig@mycosmeticsurgeon.md | |
| Principal Investigator: Richard Greco, M.D. | |
| United States, Illinois | |
| Northwestern Memorial Hospital | Recruiting |
| Chicago, Illinois, United States, 60611-2923 | |
| Contact: John Kim, M.D. 312-266-6240 jokim@nmh.org | |
| Contact: Neil Fine, M.D. 312-266-6240 nfinemd.@gmail.com | |
| Principal Investigator: John Kim, M.D. | |
| Sub-Investigator: Neil Fine, M.D. | |
| United States, Massachusetts | |
| Brigham and Women's Hospital | Recruiting |
| Boston, Massachusetts, United States, 02115 | |
| Contact: Yoon Chun, MD 617-983-4600 YCHUN@PARTNERS.ORG | |
| Contact: Gretchen Guldbrandsen 617-983-4600 GGULDBRANDSEN@PARTNERS.ORG | |
| Principal Investigator: Yoon Chun, M.D. | |
| United States, Michigan | |
| University of Michigan Medical Center | Recruiting |
| Ann Arbor, Michigan, United States, 48109 | |
| Contact: Edwin G. Wilkins, M.D., M.S. 734-936-6680 ewilkins@umich.edu | |
| Contact: Brigid Rowell, M.A. 734-998-5622 browell@umich.edu | |
| Principal Investigator: Edwin G. Wilkins, MD, MS | |
| St. Joseph's Mercy Health System | Recruiting |
| Ann Arbor, Michigan, United States, 48197 | |
| Contact: Daniel Sherick, M.D. 734-712-2323 dsherick@comcast.net | |
| Contact: Brigid Rowell, M.S. 734-998-5622 browell@umich.edu | |
| Principal Investigator: Daniel G. Sherick, M.D. | |
| United States, New Hampshire | |
| Dartmouth Hitchcock Medical Center | Recruiting |
| Lebanon, New Hampshire, United States, 03756 | |
| Contact: Dale C. Vidal, M.D. 603-650-5628 Dale.c.vidal@hitchcock.org | |
| Contact: Tracy Frazee, B.A. (603) 650-0328 Tracy.E.Frazee@Hitchcock.org | |
| Principal Investigator: Dale C. Vidal, M.D. | |
| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Andrea L Pusic, MD MHSA 212-639-5085 pusica@mskcc.org | |
| Contact: Meghan Lee, B.A. 646-227-2380 LeeM5@mskcc.org | |
| Principal Investigator: Andrea L. Pusic, MD, MHSA | |
| United States, Ohio | |
| Ohio State University Medical Center | Recruiting |
| Columbus, Ohio, United States, 43212-3154 | |
| Contact: Gayle Gordillo, M.D. 614-239-8566 gayle.gordillo@osumc.edu | |
| Contact: Kimberly Langhorne 614-366-0340 kimberly.langhorne@osumc.edu | |
| Principal Investigator: Gayle Gordillo, M.D. | |
| Sub-Investigator: James Boehmler, M.D. | |
| United States, Texas | |
| M.D. Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Steve Kronowitz, M.D. 713-794-1247 skronowi@mdanderson.org | |
| Contact: Joffee Mathews 713-745-7355 JMathews1@mdanderson.org | |
| Principal Investigator: Steve Kronowitz, M.D. | |
| Canada, British Columbia | |
| Providence Health Care - University of British Columbia | Recruiting |
| Vancouver, British Columbia, Canada | |
| Contact: Nancy Van Laeken, M.D. 604-669-1633 nvanlaeken@providencehealth.bc.ca | |
| Contact: Julianna Kowal 604-682-2344 ext 62883 JKowal@providencehealth.bc.ca | |
| Principal Investigator: Nancy Van Laeken, M.D. | |
| Canada, Manitoba | |
| University of Manitoba | Recruiting |
| Winnipeg, Manitoba, Canada, R3A 1R9 | |
| Contact: Ed Buchel, M.D. 204-787-1485 ebuchel@hsc.mb.ca | |
| Contact: Kimberly R Dalke, M.S. 204-787-3915 k.r.dalke@gmail.com | |
| Principal Investigator: Ed Buchel, M.D. | |
| Principal Investigator: | Edwin G Wilkins, MD, MS | University of Michigan |
| Principal Investigator: | Andrea L. Pusic, MD, MHSA | Memorial Sloan-Kettering Cancer Center |
More Information
Publications:
| Responsible Party: | Edwin G. Wilkins, Professor of Surgery, University of Michigan |
| ClinicalTrials.gov Identifier: | NCT01723423 History of Changes |
| Other Study ID Numbers: | 10-PAF07150 |
| Study First Received: | February 29, 2012 |
| Last Updated: | January 24, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Michigan:
|
breast cancer evidence based medicine reconstruction |
mastectomy outcomes quality of life |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on May 19, 2013